Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance)
Open Access
- 21 October 2026
- journal article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Abstract
Background: We sought to evaluate the associations of postdiagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial. Methods: We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months postrandom assignment. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (OS) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods. Results: Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not statistically significantly associated with survival outcomes, with a hazard ratio of 1.01 (95% CI = 0.75 to 1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate statistically significant associations with DFS or overall survival after Bonferroni correction. Conclusion: Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier: NCT01150045.Keywords
Funding Information
- National Institutes of Health (U10 CA180821)
- National Institutes of Health (U10 CA180882)
- National Institutes of Health (U24 CA196171)
This publication has 20 references indexed in Scilit:
- Flavonoid intake and survival after diagnosis of colorectal cancer: a prospective study in 2 US cohortsThe American Journal of Clinical Nutrition, 2023
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon CancerJAMA, 2021
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThe Lancet Oncology, 2020
- Dietary flavonoids and flavonoid-rich foods: validity and reproducibility of FFQ-derived intake estimatesPublic Health Nutrition, 2020
- Flavonoid intake is associated with lower mortality in the Danish Diet Cancer and Health CohortNature Communications, 2019
- Duration of Adjuvant Chemotherapy for Stage III Colon CancerNew England Journal of Medicine, 2018
- Dietary flavonoids, lignans and colorectal cancer prognosisScientific Reports, 2015
- Nutritional Epidemiology2012
- Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon CancerJAMA, 2007
- Validation of a semi-quantitative food frequency questionnaire: Comparison with a 1-year diet recordJournal of the American Dietetic Association, 1987